BPG is committed to discovery and dissemination of knowledge
Featured Articles
1/20/2021 2:51:17 PM | Browse: 480 | Download: 1250
 |
Received |
|
2020-07-15 11:59 |
|
Peer-Review Started |
|
2020-07-14 06:43 |
|
First Decision by Editorial Office Director |
|
2020-09-29 18:52 |
|
Return for Revision |
|
2020-09-29 18:52 |
|
Revised |
|
2020-10-17 04:27 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-11-04 10:10 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-11-09 01:20 |
|
Articles in Press |
|
2020-11-09 01:20 |
|
Edit the Manuscript by Language Editor |
|
2020-11-15 20:40 |
|
Typeset the Manuscript |
|
2021-01-12 06:17 |
|
Publish the Manuscript Online |
|
2021-01-20 12:47 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Clinical benefit of COX-2 inhibitors in the adjuvant chemotherapy of advanced non-small cell lung cancer: A systematic review and meta-analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yu-Qiong Xu, Xiang Long, Ming Han, Ming-Qiang Huang, Jia-Fa Lu, Xue-Dong Sun and Wei Han |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| The Sanming Project of Medicine in Shenzhen |
SZSM201911007 |
|
| Corresponding Author |
Wei Han, MD, Associate Chief Physician, Department of Emergency Medicine, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, No.1098 Xueyuan Avenue, Shenzhen 518000, Guangdong Province, China. weihan_dem@163.com |
| Key Words |
Non-small cell lung cancer; COX-2; Survival; Progression-free survival; Systematic review; Randomized controlled trials |
| Core Tip |
This study demonstrated that, in terms of overall response rate (ORR) for patients received adjuvant chemotherapy of advanced non-small cell lung cancer, COX-2 inhibitors improved the ORR and have no improvement on prolonged mortality. However, particularly with first-line chemotherapy, the COX-2 could enhance both the ORR and improved the 1-year survival rate. Concerning toxicity, celecoxib plus chemotherapy resulted in a higher incidence of hematologic toxicities. Meanwhile, the rofecoxib may augment the risk of cardiovascular events. |
| Publish Date |
2021-01-20 12:47 |
| Citation |
Xu YQ, Long X, Han M, Huang MQ, Lu JF, Sun XD, Han W. Clinical benefit of COX-2 inhibitors in the adjuvant chemotherapy of advanced non-small cell lung cancer: A systematic review and meta-analysis. World J Clin Cases 2020; 9(3): 581-601 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i3/581.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i3.581 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
